Navigation Links
Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine
Date:6/19/2013

Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements, among others, relating to our future capital requirements and the sufficiency of our current assets to meet these requirements, our future results of operations, our expectations for and timing of ongoing or future clinical trials and regulatory approvals for any of our product candidates, and our plans, objectives, expectations and intentions. Because these statements apply to future events, they are subject to risks and uncertainties. When used in this announcement, the words "anticipate", "believe", "estimate", "expect", "expectation", "should", "would", "project", "plan", "predict", "intend" and similar expressions are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to us and are subject to a number of risks, uncertainties and other factors that could cause our actual results, performance or achievements to differ materially from those projected in, or implied by, these forward-looking statements. Factors that may cause such a difference include, without limitation, our need for substantial additional financing and the availability and terms of any such financing, the safety and/or efficacy results of clinical trials of our product candidates, our failure to obtain regulatory approvals or comply with ongoing governmental regulation, our ability to commercialize, manufacture and achieve market acceptance of any of our product candidates, for which we rely heavily on collaboration with third parties, and our ability to protect and enforce our intellectual property rights and to operate without infringing upon the proprietary rights of third parties. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, performance or achievements and no assurance can be given that the actual
'/>"/>
SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
2. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
3. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
4. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
5. Ibrutinib Receives Two Oncology Breakthrough Therapy Designations from U.S. Food and Drug Administration
6. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
7. Phase II Ibrutinib Monotherapy Study Shows CLL Patients Achieved Rapid and Sustainable Disease Control Irrespective of Age or High Risk Prognostic Factor
8. Ibrutinib Expanded Access Program Open to Eligible U.S. Patients with Relapsed or Refractory Mantle Cell Lymphoma
9. Ibrutinib Phase 2 Data: Analyses Show Efficacy with Ibrutinib Monotherapy in Patients with Relapsed or Refractory Mantle Cell or Diffuse Large B-cell Lymphoma
10. Updated Results of Two Phase 2 Ibrutinib Studies in Patients with Mantle Cell Lymphoma or Diffuse Large B-cell Lymphoma
11. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Massachusetts General Hospital ... AMGN ) announced today that they have ... validate new therapeutic targets and develop novel therapies ... that affects millions worldwide. The MGH-Broad-Amgen collaboration brings ...
(Date:1/15/2014)... 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will ... Journal of Drugs in Dermatology (JDD) at ... The event is January 17-20, 2014, at the Omni Orlando Resort ... The ODAC is a distinguished event that ...
(Date:1/15/2014)... LOUISVILLE, Ky. , Jan. 15, 2014  Manufacturers, ... technologies must be able to protect their most ... (Logo: http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because ... Industry, it steadfastly remains one of the most ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Intellectual Property Insurance for Medical-related Products and Services 2
(Date:7/10/2014)... on aggression, who research issues ranging from child abuse ... Meeting of the International Society for Research on Aggression ... Georgia State University is hosting the prestigious world meeting, ... , "We are excited to be bringing together leading ... help produce fresh ideas about the causes, consequences and ...
(Date:7/10/2014)... The U.S. Department of Health and Human Services ... (UH) Case Medical Center Seidman Cancer Center totaling $4.7 ... improving care for patients with complex cancer. , ... unique model developed at UH to enhance care for ... demonstrated need for high health care utilization. ...
(Date:7/10/2014)... shown that more severe illness and even death are ... infection after developing influenza. Now, however, a team of ... if you reverse the order of infection, the bacteria ... protect against a bad case of the flu. ... which is described as a bacterial virulence factor, might ...
(Date:7/10/2014)... Biomedical Research Institute (IDIBELL) and the Catalan Institute of ... new therapeutic combination to combat resistant sarcomas. The clinical ... stabilize the growth of these tumors have been published ... ., Sarcomas , Sarcomas are a rare type ... It can affect from children to older ages. It ...
(Date:7/9/2014)... The World Health Organization recommends that youth participate in ... physical activity (MVPA) each day. Studies have shown ... hours. Therefore, it stands to reason that increasing ... In a new study scheduled for publication in The ... spent outdoors after school was positively associated with MVPA. ...
Breaking Medicine News(10 mins):Health News:Georgia State hosts national conference on aggression 2Health News:Georgia State hosts national conference on aggression 3Health News:UH Case Medical Center awarded $4.7 million grant from HHS 2Health News:UH Case Medical Center awarded $4.7 million grant from HHS 3Health News:Bacterial colonization prior to catching the flu may protect against severe illness 2Health News:New therapeutic combination to slow resistant sarcomas 2Health News:Go play outside! Outdoor time promotes physical activity in youth 2
... June 4 The Minneapolis-St. Paul office of Weber ... Program to head the organization,s largest annual awareness campaign. ... 8-22, will work to reach a diverse audience of ... thousands of people with leukemia and other life-threatening diseases, ...
... June 4 A cooking revolution is underway in the Kiboga district ... that the double Rocket Lorena stove is making it easier to cook ... money maker for youth in the community and are not as harmful ... out a local mixture of grass, water and mud. And for youth ...
... Mich. At the ends of chromosome are special pieces of ... caps off a shoelace. The telomeres send signals to the cells ... that should be repaired. Over time, as cells reproduce, the ... cells then have a higher risk of mutating into cancer. ...
... congestion is an important mediator in heart failure, reports ... Journal of Cardiac Failure ( http://www.onlinejcf.com/ ), published ... venous endothelium is a key regulator of central blood ... The present study demonstrates that in venous endothelium, ...
... ... Approval , ... June 4, 2009-- A new wrinkle-smoother will be arriving in doctors, offices in July: ... Union, Brazil, Argentina and more than 26 countries worldwide is a form of botulinum ...
... Nutrition Program from Fitness Expert Monique Hollowell , ... their bodies will never be the same following pregnancy ... pregnancy, less painful birth and quick recovery back to ... trainer, Monique Hollowell has created a fitness and nutrition ...
Cached Medicine News:Health News:Weber Shandwick Chosen By National Marrow Donor Program(R) To Head Awareness Campaign 2Health News:Weber Shandwick Chosen By National Marrow Donor Program(R) To Head Awareness Campaign 3Health News:Youth-made Stoves Provide Income, Protect the Environment 2Health News:Study gives clues to how adrenal cancer forms 2Health News:New Option for Erasing Wrinkles 2Health News:New Option for Erasing Wrinkles 3Health News:New Option for Erasing Wrinkles 4Health News:Keys to a Fit Pregnancy and Losing the Baby Weight 2Health News:Keys to a Fit Pregnancy and Losing the Baby Weight 3
Fluar objectives have been designed especially for qualitative and quantitative analyses of ion movements and for particularly critical fluorescence methods (e.g. chromosome studies in human and cyto...
... high-power, apochromatically corrected objectives ... the most exacting demands ... are suitable for visual ... 25 mm and feature ...
... transmission rate in the ultraviolet down to ... fluor-3; these objectives have,improved signal to noise ... Numerical Apertures for significantly sharper and brighter ... and a 2mm working distance to allow ...
... distances with high Numerical Apertures, these objectives ... aberrations throughout the visible spectrum from violet ... the entire 25mm field of view. They ... reproduction, plus resolving power at the theoretical ...
Medicine Products: